年轻成人、中年与老年风湿病患者自我注射TNF抑制剂依从性与持续性的长期变化
该回顾性队列研究利用Truven Health MarketScan数据库(2009–2013年),纳入53,477例新启用依那西普、阿达木单抗、培塞利珠单抗或戈利木单抗的风湿病患者,评估12个月药物持有率(MPR≥0.80为依从)及每12个月无≥92天治疗间隙的持续性。结果显示第一年总体依从率37%、持续率83%,年轻成人第三年依从率仅17%、持续率70%;与老年患者相比,中年和年轻成人依从可能性更低。
要点
- 第一年总体依从率37%、持续率83%,年轻成人第三年依从率17%、持续率70%。
- 与老年患者相比,中年(OR=0.73)和年轻成人(OR=0.50)依从可能性更低。
- 较高Charlson合并症评分、住院和急诊就诊与非依从/非持续相关。
核心结论
- 自我注射TNF抑制剂总体依从率低,但多数患者随时间保持持续治疗。
- 年轻成人和合并症较多的患者依从性更差,需针对性改善。
研究设计与样本
- 回顾性队列研究,使用Truven Health MarketScan数据库2009–2013年数据。
- 纳入53,477例18岁及以上新启用依那西普、阿达木单抗、培塞利珠单抗或戈利木单抗的风湿病患者。
- 按年龄分组:年轻成人(18-34岁)占14%,中年(35-54岁)占49%,老年(55岁及以上)占37%。
- 采用药房配药数据计算12个月MPR(MPR≥0.80为依从),评估起始治疗后最多3年的依从性。
- 持续性定义为每个12个月区间内无≥92天治疗间隙,采用多变量广义估计方程模型计算OR和稳健95%CI。
主要发现
- 第一年总体37%的患者依从,83%的患者持续。
- 年轻成人患者第三年依从率最低(17%),持续率最低(70%)。
- 与老年患者相比,中年患者依从的OR=0.73(95%CI: 0.71-0.76),年轻成人OR=0.50(95%CI: 0.47-0.53)。
- 较高Charlson合并症评分、住院和急诊就诊与非依从/非持续相关。
关键数值与推荐
- 依从定义为12个月MPR≥0.80。
- 持续定义为每个12个月区间内无≥92天治疗间隙。
- 年龄分组:年轻成人18-34岁,中年35-54岁,老年55岁及以上。
临床怎么用
- 对年轻成人及合并症较多、有住院或急诊就诊史的患者应加强依从性监测与干预。
- 尽管持续率较高,但总体依从率低,需在随访中常规评估用药依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Self-injectable TNF inhibitors are increasingly used early in the chronic treatment of moderate to severe rheumatologic conditions. We estimated medication adherence/persistence over time following initiation in young adult and older adult patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. METHODS: We conducted a retrospective cohort study of patients aged 18+ years newly initiating etanercept, adalimumab, certolizumab pegol, or golimumab using the Truven Health MarketScan Database between 2009 and 2013. Pharmacy dispensing data were used to calculate 12-month medication possession ratios (MPR) and determine adherence (MPR ≥ 0.80) for up to 3 years after starting therapy. Persistence over each 12-month interval was defined as not having a ≥92-day treatment gap. Multivariable generalized estimating equation models were used to calculate odds ratios (OR) and robust 95% confidence intervals (CI) for associations between patient characteristics and repeated adherence/persistence measures over time. RESULTS: Among 53,477 new users, 14% were young adults (18-34 years), 49% middle-aged (35-54 years), and 37% older adults (55+ years). Overall, 37% of patients were adherent and 83% were persistent in the first year of therapy. The lowest adherence (17%) and persistence (70%) were observed among young adult patients by Year +3. Compared to older adults, middle-aged (OR = 0.73, 95% CI: 0.71-0.76) and young adults (OR = 0.50, 95% CI: 0.47-0.53) were less likely to be adherent. Higher Charlson comorbidity scores, hospitalizations, and emergency department visits were associated with non-adherence/non-persistence. CONCLUSIONS: We observed low adherence to self-administered TNF inhibitors but most patients remained persistent over time. Further efforts to improve adherence in young adults and patients with greater comorbidity are needed.
引用
- Calip GS, Adimadhyam S, Xing S, et al. Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions. Semin Arthritis Rheum. 2017. PMID: 28410817. doi:10.1016/j.semarthrit.2017.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。